Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 25, 2022Journal of Clinical MedicineOpen Access

Correction of iron deficiency using intravenous iron (ferric carboxymaltose) provides improvements in symptoms of HF, exercise capacity, and quality of life, and reduces the risk of subsequent HF hospitalizations following acute decompensated HF.

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Despite its negative clinical consequences in heart failure, iron deficiency remains under-recognised, prompting the need for practical guidance on screening, diagnosing, and treating it.

Design

Review

Authors

ASAndrew SindoneWDWolfram DoehnerNMNicolás Manito

Discussion

Loading...

Member takes

Overview

May identify a modifiable risk factor independent of anemia; leaves open optimal repletion strategies in modern HF care.

Structured PICO

P
Population
Patients with symptomatic heart failure with reduced ejection fraction (HFrEF) and iron deficiency
I
Intervention
Intravenous iron (principally ferric carboxymaltose)

This review provides practical guidance on screening, diagnosing, and treating iron deficiency in patients with HFrEF using intravenous iron, in alignment with the 2021 ESC guidelines.

Cite This Study

Sindone et al. (2022) studied this question.

synapsesocial.com/papers/6a7eb34e358787acda4f7b8fhttps://doi.org/10.3390/jcm11112976
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Iron Deficiency in Heart Failure: Cellular Mechanisms and Therapeutic Implications2025 · 7 citations
  2. 2Iron Deficiency in Heart Failure – the Relevance for the Patient2015
  3. 3Treatment of iron deficiency in patients after acute decompensation: a new target in the treatment of heart failure2022 · 4 citations
  4. 4The role of iron deficiency in heart failure2023 · 5 citations
  5. 5Iron Deficiency in Heart Failure: Unveiling the Hidden Culprit2024